Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maximum tolerated dose (MTD) of the combination (CarPan) and assess safety and efficacy among RRMM patients. Thirty-two patients (median of 4 prior lines of therapy) were enrolled. The MTD was carfilzomib 36 mg/m 2 (on days 1, 2, 8, 9, 15, and 16) and panobinostat 20 mg (TIW, 3 weeks on/1 week off, every 28 days), administered until progression. At the MTD, the most common grade 3/4, treatment-related adverse events were thrombocytopenia (41%), fatigue (17%), and nausea/vomiting (12%). The objective response rate (ORR) and clinical benefit rate were 63% and 68%, respectively. Median progression-free survival (PFS) and overall survival (OS) for the entire population were 8 and 23 months, respectively. No differences in terms of ORR (55% vs. 57%), median PFS (months 8 vs. 7 months) and OS (24 vs. 22 months) were observed between bortezomib-sensitive and -refractory patients. CarPan proved to be a safe and effective steroid-sparing regimen in a heavily pre-treated population of MM patients. (Trial registered at ClinicalTrial.gov: NCT01549431)
Introduction
Multiple myeloma (MM) is a neoplasm characterized by a clonal proliferation of plasma cells in the bone marrow and the accumulation of monoclonal protein in serum and/or urine, with related organ dysfunction. MM is the second most common hematologic malignancy, accounting for 10% of all hematologic malignancies and 1% of all cancers 1 . In the last 15 years, the introduction of the first-generation novel agents-the proteasome inhibitor (PI) bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide-has revolutionized treatment and led to a dramatic improvement in the survival of MM patients 2, 3 . However, despite the great efficacy displayed by newer agents, relapse is still inevitable and the prognosis of patients relapsing after firstgeneration PIs and IMiDs has been shown to be extremely poor 4 . This led to the investigation and the approval of next-generation PIs (carfilzomib, ixazomib) and the IMiD pomalidomide, as well as agents with novel mechanisms of action, such as monoclonal antibodies (elotuzumab and daratumumab) and the histone deacetylase inhibitor (HDACi) panobinostat.
Carfilzomib, a second-generation PI, is an epoxyketone that irreversibly binds to the β5 subunit of the proteasome, preventing protein degradation by the proteasome itself and thus causing an accumulation of intracellular proteins that eventually leads to cell death via apoptosis 5 . It has significant activity among patients relapsed and/or refractory (RR) to bortezomib and IMiDs, and has been approved by American and European regulatory agencies 6, 7 . Currently, carfilzomib is approved with the twiceweekly schedule at a dose of 27 mg/m 2 , over a 2-to 10-min infusion, when given in combination with lenalidomide and dexamethasone (KRd), or at a dose of 56 mg/m 2 , over a 30-min infusion, when given alone or in combination with dexamethasone (Kd); nonetheless, other doses (up to 70 mg/m 2 ) and schedules (once versus twice weekly) have been shown to be promising 8, 9 . Panobinostat is a pan-HDACi that exerts activity on class I, II and IV HDACs, thus regulating cell cycle, cell survival and apoptosis, and intracellular protein homeostasis 10, 11 . In a phase II study, panobinostat monotherapy showed only modest activity among RRMM patients 12 . Both PIs and HDACis can regulate the metabolism on misfolded proteins, leading to their intracellular accumulation by the dual inhibition of proteasome and aggresome 13 . Based on preclinical data showing synergy between PIs and HDACis, bortezomib and panobinostat were tested in combination with dexamethasone among RRMM patients. In the placebo-controlled, phase 3 PANORAMA-1 study conducted among RRMM patients, the addition of panobinostat to bortezomib and dexamethasone (Vd) resulted in a significantly higher rate of near-complete responses (nCRs) and CRs (28% vs. 16%) as compared to placebo-Vd, and significantly prolonged median progression-free survival (PFS, 12 vs. 8 months), leading to FDA approval for RR patients who have received at least two prior therapies, including bortezomib and an IMiD 14 . Despite a remarkable clinical activity, the combination of bortezomib and panobinostat was burdened by a significant rate of grade 3/4 thrombocytopenia (64/67%) and gastrointestinal (GI) toxicity (diarrhea, 20/ 25%), more likely due to the overlapping toxicity profiles of the two anti-myeloma agents 14, 15 . In this light, to maximize the synergy between panobinostat and PIs, while optimizing the safety profile of the combination, panobinostat was tested, at different doses and schedules, with second-generation PIs (carfilzomib and ixazomib). In a phase 1/2 trial, carfilzomib and panobinostat (CarPan), the latter administered in a 1 week-on/1 week-off fashion, showed promising efficacy, 67% of heavily pre-treated patients achieving an objective response, and an acceptable safety profile 16 . In order to exploit the synergy between the two drugs, we tested the administration of carfilzomib and panobinostat, both on a 3-week-on/1-week-off schedule. Herein, we report the results of a phase 1 study investigating a steroid-sparing, CarPan doublet regimen, for the treatment of RRMM patients.
Methods

Study population
Patients with relapsed and/or refractory MM who received at least 1 previous anti-myeloma therapy were eligible. Patients previously treated with carfilzomib were excluded from the study. RRMM was defined according to the International Myeloma Working Group (IMWG) criteria 17 . Key inclusion criteria were: age ≥ 18 years; measurable disease; Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow reserves; serum creatinine clearance ≥ 30 mL per minute; adequate hepatic function (alanine aminotransferase up to The first 2 doses of carfilzomib in cycle 1 were administered at 20 mg/m 2 and premedication with dexamethasone 4 mg was mandatory prior to each dose of carfilzomib during cycle 1 and was thereafter administered as clinically indicated b Three times a week 2.5 times and bilirubin up to 1.5 times of the upper normal limit). Exclusion criteria were history or presence of ventricular arrhythmias; a baseline electrocardiogram (EKG) with a QTc interval > 450 msec, uncontrolled hypertension; unstable angina or myocardial infarction within 6 months prior to enrollment, NYHA Class III or IV heart failure; impairment of GI function or GI disease that may significantly alter the absorption of panobinostat. The institutional review board at each participating center approved the study in accordance with the Declaration of Helsinki. All patients provided written informed consent. This trial was registered at Clinicatrials.gov as NCT01549431.
Study design
This is a multi-center, phase 1 open-label study. In the dose-escalation portion of the trial, the primary endpoint was the maximum tolerated dose (MTD) of panobinostat and carfilzomib when given in combination. Patients were evaluated for dose-limiting toxicity (DLT) according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. A standard 3 + 3 dose-escalation schedule was used, starting from dose level 1 with up to 4 sequential dose-escalating cohorts with 3 to 6 patients in each cohort (Table 1) . A DLT was defined as any treatment-emergent toxicity attributable to at least 1 of the study drugs occurring during cycle 1. Non-hematologic DLTs included: ≥ grade 2 cardiac toxicity involving either QTc prolongation or congestive heart failure; any grade ≥ 3 toxicity; any non-hematologic toxicity requiring a dose reduction or dose interruption in cycle 1. Hematologic DLTs included: grade 4 neutropenia lasting for ≥ 7 days and febrile neutropenia; grade 4 thrombocytopenia associated with bleeding or requiring more than one platelet transfusion; and a > 7-day delay in receiving the day-1 dose of cycle 2 due to inadequate recovery of platelets ( < 75 × 10 9 /L) or other drug-related toxicity persisting from cycle 1.
In the expansion phase of the trial, 12 additional patients were enrolled and treated at the MTD of panobinostat and carfilzomib to support the secondary objectives of the study including toxicity profile of the combination; objective response rate (ORR); duration of response (DOR); PFS and overall survival (OS). In the exploratory analysis, we evaluated the impact of international staging system (ISS), prior exposure to bortezomib and/or lenalidomide and disease status (refractoriness to bortezomib) on response rate, PFS and OS.
Study procedures
Salvage treatment with CarPan consisted of 28-day cycles with twice-weekly carfilzomib (20 mg/m 2 intravenously on day 1 and 2 cycle 1, then at a higher dose 
Statistical analysis
The sample size of the phase 1 portion was based on the scenario that cohorts (dose levels 1-4) consisted of 3 to 6 patients. The sample size of the expansion phase was based on the probability of 53.5% (confidence level) that the toxicity level of the MTD was within the range of 18 to 33%. All patients who completed at least 1 cycle of the assigned treatment or discontinued treatment during the first cycle due to toxicity were evaluable for safety; patients who started treatment and had at least one on study anti-myeloma assessment were evaluable for efficacy. Comparisons between different patient groups were investigated using Fisher's exact test. Time to response was calculated from the start of treatment to the date of the first response (CR, very good partial response [VGPR], PR, minimal response [MR]). PFS was calculated from date of entry into the trial to the date of progression or death or the date the patient was last known to be in remission. OS was calculated from date of entry into the trial to the date of death or the date the patient was last known to be alive. Time-to-event data were analyzed using the Kaplan-Meier method. The individual effects on PFS and OS of ISS and disease refractoriness to bortezomib were evaluated using Cox proportional hazards models. Results are presented as hazard ratios (HRs) and 95% confidence intervals (95% CIs). Data were analyzed using R software (Version 3.1.1).
Safety and response criteria
Responses were recorded at the beginning of every cycle, according to the IMWG criteria 19 ; MR was defined as a decrease in the monoclonal component between 25 and 49% from baseline.
Results
Patient characteristics
Between February 2012 and July 2015, 32 RRMM patients were enrolled at three centers. Patient characteristics are listed in Table 2 . The median age at enrollment was 66 years (range, 50-76 years). The median number of previous lines of therapy was 4 (range, 1-8), and the median time from diagnosis to enrollment was 6 years (range, 1-13 years). Twenty-seven patients (84%) were relapsed and refractory to their last line of treatment. Twenty-nine patients (91%) had previously received bortezomib; of them, 17 (53%) were bortezomib refractory. Twenty-nine (91%) patients had previously received lenalidomide; of them 10 (31%) were refractory. Eight patients (25%) were double refractory to both bortezomib and lenalidomide. Thirty out of 32 patients (94%) underwent a previous autologous stem cell transplant. At the time of data cut-off for statistical analysis, all patients had discontinued treatment, mostly due to disease progression (78%), while 19% of patients stopped treatment due to the occurrence of AEs.
Maximum tolerated dose
Dose levels and the observed DLTs are listed in Table 3 . Four patients (1 unevaluable due to rapid disease progression) were enrolled in the first dosing cohort (carfilzomib 27 mg/m 2 , panobinostat 15 mg) with no DLT. In the second cohort, carfilzomib (27 mg/m 2 ) and panobinostat (20 mg), no DLT was reported among the 3 patients evaluable (per protocol, 1 patient was not evaluable as he did not receive the treatment as planned due to missed doses not related to AEs). In cohort 3 (carfilzomib 36 mg/m 2 , panobinostat 20 mg), 1 of the 3 patients enrolled experienced a grade 3 creatinine increase and a grade 4 thrombocytopenia in cycle 1, necessitating 3 additional enrolled patients, none of whom had a DLT. Hence, the dose of carfilzomib was escalated. In cohort 4 (carfilzomib 45 mg/m 2 , panobinostat 20 mg) two DLTs were observed, a grade 4 thrombocytopenia and a grade 3 diarrhea. The MTD of the combination was then determined to be carfilzomib 36 mg/m 2 with panobinostat 20 mg. An additional 12 patients were enrolled at the MTD, for a total of 18 patients at this dose level; of them, 16 were evaluable for efficacy.
Safety
Treatment-related AEs are listed in Table 4 . Per protocol, 30 patients were evaluable for toxicities. Eleven patients (37%) had at least 1 treatment-related serious adverse event (SAE). Any grade hematological treatmentrelated AEs occurred in 29 of 30 patients (97%), while grade 3/4 hematological AEs occurred in 19 (63%) patients, including thrombocytopenia in 14 (47%), anemia in 9 (30%) and neutropenia in 6 (20%) patients. Any grade non-hematological treatment-emergent AEs were observed in 28 (93%) patients; grade 3/4 nonhematological AEs were reported in 17 (57%) patients, and the most frequent were gastrointestinal events, with nausea and vomiting, diarrhea and anorexia in 7% of patients each, fatigue (17%), and hypophosphatemia (10%). Any grade and grade 3-4 cardiac AEs occurred in 6 (20%) and 1 (3%) patients, respectively. One grade 5 AE (cardiac arrest) was observed during cycle 2 (cohort 1) in a patient with no cardiovascular comorbidities, a normal 
Creatinine increase 5 (17) 2 (7) 2 (12) 1 (6) 
Percentage may not total 100% due to rounding baseline EKG and no significant EKG alterations, including QT prolongation, study during treatment, and normal echocardiogram study; this event was attributed to be study related. Patients were monitored with EKG during treatment: in 4 (13%) patients a prolongation in the QT interval was registered during routine EKG, however only 1 event was reported as a grade 1 AE (3%). Any grade and grade 3/4 hypertension were observed in 7 (23%) and 2 (5%) patients. A low rate of any grade peripheral neuropathy was reported (10%), without any grade 3-4 events. At least 1 dose reduction of carfilzomib was necessary in 7 patients (23%) while the dose of panobinostat was reduced in 13 patients (43%). AEs leading to treatment discontinuation were thrombocytopenia (n = 2), acute pancreatitis (n = 1), cardiac arrest (n = 1), bowel perforation (n = 1), and congestive heart failure (n = 1).
Efficacy
Per protocol, 30 patients were evaluable for efficacy (Table 5) . Patients received a median of 8 cycles (range, 1-23 cycles) of study treatment. The ORR in the overall population was 57%; 10 patients achieved PR (33%), 5 VGPR (17%), and 2 CR (7%). Taking into account 4 patients who had a MR (13%), the clinical benefit rate (CBR) was 70%. Among patients treated at the MTD of carfilzomib and panobinostat the ORR was 63%, and 25% of patients achieved VGPR or better. The median time to at least PR was 2 months, and the median duration of response was 9 months. No differences were observed among bortezomib refractory and bortezomib-sensitive patients in terms of ORR (57% vs. 55%; p = 1) and at least VGPR rate (25% vs. 18%; p = 1). Moreover, in patients previously exposed to both bortezomib and lenalidomide, CarPan was able to induce an objective response in 48% of them, with a CBR rate of 65%.
No differences in ORR and at least VGPR rate were reported among patients with ISS 1 (56% and 61%, respectively) or ISS 2-3 (50% and 67%, respectively). After a median follow-up of 27 months, median PFS and OS in Bortezomib and lenalidomide refractory n = 30 n = 16 n = 11 n = 16 n = 23 (23) 4 (25) 2 (7) 4 (13) 4 (17) 
Discussion
In this phase 1 study, the MTD of the CarPan regimen was panobinostat 20 mg, administered 3 times weekly in a 3-week-on/1-week-off schedule, in combination with twice-weekly carfilzomib at the dose of 36 mg/m 2 . The most common AEs were hematological, mainly thrombocytopenia, and GI, including nausea, vomiting and diarrhea. In a heavily pre-treated population, in which patients have received a median of 4 prior lines of therapies and 84% of patients were relapsed and refractory to their last line of treatment, the MTD of CarPan showed promising results in terms of ORR (63%) and PFS (median, 8 months). Based on preclinical studies showing synergism between HDACis and PI (mediated by a double blockade of the intracellular protein degradation system) and evidence of a modest anti-myeloma activity displayed by single agent panobinostat, the combination of panobinostat and Vd has been tested 12, 13 . The phase 2 PANORAMA-2 trial tested panobinostat, 20 mg in a 2-week-on/1-week-off schedule, with Vd in a bortezomib refractory population 15 . The addition of panobinostat to Vd was able to re-capture an objective response in 35% of the patients. Despite the evident clinical activity, panobinostat-Vd also showed a significant toxicity profile, mainly consisting of thrombocytopenia (grade 3-4, 64%), GI AEs such as diarrhea (grade 3-4, 20%), and fatigue (grade 3-4, 20%). Similar results were confirmed by the phase 3 PANORAMA-1 14 .
Carfilzomib is a second generation PI with significant activity, even among bortezomib exposed patients, that has been combined with panobinostat, at different doses and schedules, in early phase trials (NCT01301807, NCT01549431, NCT01496118) 20 . We tested escalating doses of panobinostat (up to 20 mg) administered 3 times a week in a 3-week-on/1-week-off schedule, to fit with the standard schedule of carfilzomib (twice weekly, 3 weeks on/1 week off) and maximize the synergy between proteasome and HDAC inhibition. Three out of 4 DLTs were hematological (grade 4 thrombocytopenia, n = 2) and GI (grade 3 diarrhea, n = 1) in nature. Thrombocytopenia is a well-known HDACi class-effect, due to the inhibition of maturation of megakaryocytes and the release of proplatelets. It has been shown that it rapidly reverses withholding the drug; hence, it is possible that a different schedule might allow higher dose of panobinostat and 
